Table 1 Baseline clinical characteristics and laboratory observations
From: Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
Patient | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
Age | 40 | 21 | 52 | 60 | 68 | 42 |
Sex | M | F | M | F | F | F |
Admission – days after vaccination | 9 | 12 | 9 | 41 | 16 | 59 |
Prior exposure to a heparin | No | No | No | Yes | No | No |
Hemoglobin (M134–167, F 117–155 g/L) | 147 | 106 | 146 | 116 | N/A | N/A |
WBC Count (× 109/L) (3.4–8.2 × 109/L) | 6.1 | 5.5 | 5.4 | 5 | N/A | N/A |
Neutrophilia or monocytosis | Yes | No | Yes | Yes | N/A | N/A |
ALT (U/L) (< 50 U/L) | 127 | 12 | 55 | 55 | N/A | N/A |